3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
36
Cholangiocarcinoma
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
5
Liver Neoplasms
5
Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Liver Diseases
2
Kidney Neoplasms
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Breast Neoplasms
2
Advanced Solid Tumor
2
von Hippel-Lindau Disease
1
Urogenital Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Penile Neoplasms
1
Interventions
Cisplatin
20
Radiotherapy
16
Paclitaxel
14
Carboplatin
12
pembrolizumab
11
Drug Therapy
11
tislelizumab
10
Fluorouracil
8
Neoadjuvant Therapy
7
130-nm albumin-bound paclitaxel
7
sintilimab
5
Esophagectomy
5
toripalimab
4
Tegafur
4
TP protocol
4
Nivolumab
4
Irinotecan
4
Immunotherapy
4
spartalizumab
3
S 1 (combination)
3
Oxaliplatin
3
Leucovorin
3
Itraconazole
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
nimotuzumab
2
apatinib
2
Taxes
2
Radiotherapy, Intensity-Modulated
2
Immune Checkpoint Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Squamous Cell Carcinoma
×
lenvatinib
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled